Kite Pharma Overview
Pro stress-test →Kite Pharma, a Gilead Company subsidiary, is a biotechnology firm specializing in cancer immunotherapy with a primary focus on genetically engineered CAR T cell therapy. The company is the leader in engineered T cell therapy for hematologic malignancies. Cell therapy specialists at Kite manufacturing facilities reengineer a patient's own immune cells to attack and fight their cancer cells—one patient at a time.
Strategic Profile
Pro stress-test →After recalibrating its production strategy in the late 2010s to better meet CAR-T market realities, Kite is preparing for potential approval of next-generation multiple myeloma cell therapy. The company expects to employ more than 500 full-time staff in Maryland across both sites by the end of 2026, reflecting expansion of manufacturing capacity. Kite is also eyeing in vivo CAR-Ts to simplify manufacturing and logistical constraints, potentially bringing medicines to a greater swath of patients.
Competitive Landscape
Pro stress-test →Kite develops CAR-T cell therapies, a cell-based approach using chimeric antigen receptors and T cells. Primary competitors in the CAR-T and cell therapy space include Novartis (Kymriah), Juno Therapeutics (Beomorph), and emerging players like Legend Biotech. Kite's positioning as a Gilead subsidiary with established manufacturing infrastructure provides competitive advantages in scalability and regulatory experience.
Industry Context
Kite Pharma operates in Cell Therapy / Cancer Immunotherapy.
Key facts
Founded: 2009 · Headquarters: Santa Monica, US · Employees: 2,000 · Revenue: N/A · Market cap: N/A